BioMarin gets CHMP green light for Vimizim
This article was originally published in Scrip
Hot on the heels of FDA approval, experts on the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of BioMarin's enzyme replacement therapy Vimizim (elosulfase alfa) for the treatment of the lysosomal storage disorder Morquio A syndrome, also called mucopolysaccharidosis type IVA (MPS IVA). Earlier this month, the FDA approved Vimizim for the same indication (scripintelligence.com, 15 February 2014).
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.